or Try an Advanced Search...

    Technical Analysis for NRIX - Nurix Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 15.90 6.35% 0.95
    NRIX closed up 6.35 percent on Wednesday, May 15, 2024, on 87 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: May 20
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Up
    Historical NRIX trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Overbought Strength 0.00%
    Above Upper BB Strength 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Crossed Above 50 DMA Bullish 6.35%
    MACD Bullish Centerline Cross Bullish 6.35%
    BB Squeeze Ended Range Expansion 6.35%
    Gapped Up Strength 6.35%
    Older End-of-Day Signals for NRIX ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 14 hours ago
    Up 10% about 14 hours ago
    Up 1 ATR about 15 hours ago
    Up 5% about 15 hours ago
    Rose Above Previous Day's High about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NRIX Chart by TradingView
    Basic chart:

    Profile

    Nurix Therapeutics, Inc. Description

    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Lymphoma Enzymes Tyrosine Kinase Immune Disorders Small Molecule Therapies Gilead Sciences Bruton's Tyrosine Kinase Oncogene

    Is NRIX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 14 Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
    May 7 Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
    Apr 16 Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    Apr 15 Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
    Apr 15 Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
    Apr 12 Biggest stock movers today: NRIX and APLD
    Apr 12 Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
    Apr 12 Nurix Therapeutics prices upsized stock offering to raise $175 million
    Apr 12 Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
    Apr 11 Nurix Therapeutics announces proposed public offering
    See more NRIX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.12
    52 Week Low 4.22
    Average Volume 1,122,997
    200-Day Moving Average 9.68
    50-Day Moving Average 14.08
    20-Day Moving Average 13.55
    10-Day Moving Average 13.91
    Average True Range 1.07
    RSI (14) 63.37
    ADX 19.6
    +DI 35.10
    -DI 14.71
    Chandelier Exit (Long, 3 ATRs) 13.36
    Chandelier Exit (Short, 3 ATRs) 15.11
    Upper Bollinger Bands 15.41
    Lower Bollinger Band 11.68
    Percent B (%b) 1.13
    BandWidth 27.59
    MACD Line 0.22
    MACD Signal Line -0.04
    MACD Histogram 0.2553
    Fundamentals Value
    Market Cap 771.21 Million
    Num Shares 48.5 Million
    EPS -2.74
    Price-to-Earnings (P/E) Ratio -5.80
    Price-to-Sales 6.54
    Price-to-Book 1.84
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 17.64
    Resistance 3 (R3) 17.67 17.12 17.35
    Resistance 2 (R2) 17.12 16.68 17.11 17.25
    Resistance 1 (R1) 16.51 16.40 16.82 16.48 17.16
    Pivot Point 15.96 15.96 16.11 15.95 15.96
    Support 1 (S1) 15.35 15.52 15.66 15.32 14.64
    Support 2 (S2) 14.80 15.24 14.79 14.55
    Support 3 (S3) 14.19 14.80 14.45
    Support 4 (S4) 14.16